OMEICOS Therapeutics GmbH - Pipeline


Our clinical candidate OMT-28 is a stable synthetic small molecule analog of the natural omega-3 fatty acid metabolite 17,18-EEQ. Its structure was optimized to provide high efficacy, safety and oral bioavailability. The drug has been investigated in clinical phase I, revealing an excellent safety and tolerability profile.

Link to our Clinical Phase I trial


RZ PiplineGrafik 1024px3